Core Insights - Creative Medical Technology Holdings, Inc. has successfully generated human induced pluripotent stem cells (iPSC)-derived Islet Cells that produce human insulin, marking a significant milestone in their regenerative medicine efforts [1][3] - The iPSC clinical line used for this development is part of the iPSCelz® program, which is validated by Greenstone Biosciences Inc. and is currently utilized in several FDA cleared clinical programs [2][4] - The company aims to leverage this advancement for both clinical applications of human Islet Cells and the production of stand-alone human insulin, with ongoing strategic discussions for future collaborations [3] Company Overview - Creative Medical Technology Holdings, Inc. specializes in stem cell technology across various fields including immunotherapy, urology, neurology, and orthopedics [5] - The iPSCelz® program utilizes a xeno-free human perinatal cell line derived from qualified human donors, which is then converted into iPS cells through a proprietary reprogramming process [4] Leadership Commentary - Timothy Warbington, President and CEO, emphasized the importance of this development as a reflection of the company's leadership in therapy development and its potential to save significant research and development time and costs [3] - The company is committed to achieving milestones in a cost-efficient manner while adhering to regulatory requirements, indicating a prudent allocation of resources [3]
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin